Predictive Genetic Testing in the Cancer Management and Prevention

Predictive genetic testing is a medical test that can effectively reduce morbidity and mortality caused by genetic diseases. This specific test predicts the risk of disease and provides prognostic information in asymptomatic persons, leading to the adoption of prevention strategies and individualized treatment in high-risk persons. Although the cause of some cancers is not known correctly, numerous studies establish that some specific gene mutations make people susceptible to specific cancer. Therefore, genetic screening of people, especially individuals with a family history of cancer, can be essential in reducing disease mortality and improving survival. Although genetic screening, in some cases, is associated with challenges, overall, it can be recognized as an important way to prevent and control hereditary diseases and save many lives. This article provides a critical review of the published reports and discusses the value of preventive genetic testing in preventing and controlling cancers and the role of hereditary mutations associated with cancer development.

• Publication year

  2025

• Venue

  Journal of Cancer Science and Clinical Therapeutics

• Publication date

  2025-10-27

• Fields of study

  Medicine

• Identifiers
  DOI 10.26502/jcsct.5079274PMID 41541272PMCID 12802875
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The Association Between Early Progesterone Rise and Serum Estradiol Levels as Well as Endometrial Thickness in IVF Cycles

  2025cited by this paper
• Decoding pancreatic cancer: key risk factors across genetics and lifestyle

  2025cited by this paper
• Cancer statistics, 2025

  2025cited by this paper
• Comparing Prognosis for BRCA1, BRCA2, and Non-BRCA Breast Cancer

  2023influential reference
• Incidence and Prognostic Impact of Deleterious Germline Mutations in Primary Advanced Ovarian Carcinoma Patients

  2023cited by this paper
• BRCA testing and testing results among women 18–65 years old

  2022cited by this paper
• Optimal Strategies for Colorectal Cancer Screening

  2022cited by this paper
• Cancer statistics, 2022

  2022cited by this paper
• Genetic Testing

  2021cited by this paper
• Prophylactic colectomy and rectal preservation in FAP: systematic endoscopic follow-up and adenoma destruction changes natural history of polyposis

  2021cited by this paper
• Predicting breast cancer risk using interacting genetic and demographic factors and machine learning

  2020cited by this paper
• Beyond the Genomic Mutation: Rethinking the Molecular Biomarkers of K-RAS Dependency in Pancreatic Cancers

  2020cited by this paper
• MUTYH‐associated polyposis – colorectal phenotype and management

  2020cited by this paper
• Patterns and predictors of genetic referral among ovarian cancer patients at a National Cancer Institute‐Comprehensive Cancer Center

  2020cited by this paper
• Surveillance, Epidemiology, and End Results Program

  2020cited by this paper
• Re-epithelialization and immune cell behaviour in an ex vivo human skin model

  2020cited by this paper
• Potential anticancer activity of a new pro-apoptotic peptide–thioctic acid gold nanoparticle platform

  2020cited by this paper
• Pancreatic ductal adenocarcinoma progression is restrained by stromal matrix.

  2020cited by this paper
• Aspirin use and risk of breast cancer in African American women

  2020cited by this paper
• Germline sequencing DNA repair genes in 5,545 men with aggressive and non-aggressive prostate cancer.

  2020cited by this paper
• Colon Cancer: A Clinician’s Perspective in 2019

  2020cited by this paper
• Prevalence of Germline Variants in Prostate Cancer and Implications for Current Genetic Testing Guidelines

  2019cited by this paper
• Prevalence of BRCA1 and BRCA2 pathogenic and likely pathogenic variants in non-selected ovarian carcinoma patients in Brazil

  2019cited by this paper
• Reasons for Discontinuing Active Surveillance: Assessment of 21 Centres in 12 Countries in the Movember GAP3 Consortium.

  2019cited by this paper
• Hereditary Colorectal Cancer Syndromes

  2019cited by this paper
• BRCA germline mutation test for all woman with ovarian cancer?

  2019cited by this paper
• The Role of BRCA Testing in Hereditary Pancreatic and Prostate Cancer Families.

  2019cited by this paper
• The proportion of endometrial cancers associated with Lynch syndrome: a systematic review of the literature and meta-analysis

  2019cited by this paper
• Epidemiology of Prostate Cancer

  2019cited by this paper
• Population-based assessment of the performance of sigmoidoscopy in the detection of colorectal cancer: implications for future screening recommendations.

  2019cited by this paper
• Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation

  2019cited by this paper
• The budgetary impact of genetic testing for hereditary breast cancer for the statutory health insurance

  2019cited by this paper
• Consensus Guidelines on Genetic` Testing for Hereditary Breast Cancer from the American Society of Breast Surgeons

  2019cited by this paper
• Well-differentiated Pancreatic Neuroendocrine Tumor in a Patient With Familial Atypical Multiple Mole Melanoma Syndrome (FAMMM).

  2019cited by this paper
• Levonorgestrel-releasing intrauterine system use is associated with a decreased risk of ovarian and endometrial cancer, without increased risk of breast cancer. Results from the NOWAC Study.

  2018cited by this paper
• Molecular Genomic Testing for Breast Cancer: Utility for Surgeons

  2018cited by this paper
• Underdiagnosis of Hereditary Breast Cancer: Are Genetic Testing Guidelines a Tool or an Obstacle?

  2018influential reference
• Germline genetic testing for inherited prostate cancer in practice: Implications for genetic testing, precision therapy, and cascade testing

  2018cited by this paper
• Exome Sequencing–Based Screening for BRCA1/2 Expected Pathogenic Variants Among Adult Biobank Participants

  2018cited by this paper
• Anticipated health behaviour changes and perceived control in response to disclosure of genetic risk of breast and ovarian cancer: a quantitative survey study among women in the UK

  2017cited by this paper
• Epidemiology of prostate cancer

  2017cited by this paper
• Familial pancreatic cancer: Concept, management and issues

  2017cited by this paper
• Prevention of pancreatic cancer

  2017cited by this paper
• Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing

  2017cited by this paper
• Intentional Weight Loss and Endometrial Cancer Risk.

  2017cited by this paper
• Cancer risk and survival in path_MMR carriers by gene and gender up to 75 years of age: a report from the Prospective Lynch Syndrome Database

  2017cited by this paper
• Colon cancer survival in the United States by race and stage (2001‐2009): Findings from the CONCORD‐2 study

  2017cited by this paper
• Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017.

  2017cited by this paper
• Direct-to-Consumer Genetic Testing: User Motivations, Decision Making, and Perceived Utility of Results

  2017cited by this paper
• Use of BRCA Mutation Test in the U.S., 2004-2014.

  2017cited by this paper
• National Estimates of Genetic Testing in Women With a History of Breast or Ovarian Cancer.

  2017cited by this paper
• Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.

  2017cited by this paper
• Genetic Testing and Counseling Among Patients With Newly Diagnosed Breast Cancer

  2017cited by this paper
• Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers

  2017cited by this paper
• Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation

  2017cited by this paper
• A study of over 35,000 women with breast cancer tested with a 25‐gene panel of hereditary cancer genes

  2017cited by this paper
• Familial prostate cancer.

  2016cited by this paper
• Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer.

  2016cited by this paper
• Inherited Mutations in Women With Ovarian Carcinoma.

  2016cited by this paper
• Increased Proportion of Variance Explained and Prediction Accuracy of Survival of Breast Cancer Patients with Use of Whole-Genome Multiomic Profiles

  2016cited by this paper
• Continuous Combined Estrogen Plus Progestin and Endometrial Cancer: The Women's Health Initiative Randomized Trial.

  2016cited by this paper
• Lifestyle changes and the risk of developing endometrial and ovarian cancers: opportunities for prevention and management

  2016cited by this paper
• Understanding the contribution of family history to colorectal cancer risk and its clinical implications: A state‐of‐the‐science review

  2016cited by this paper
• Hereditary colorectal cancer syndromes: American Society of Clinical Oncology Clinical Practice Guideline endorsement of the familial risk-colorectal cancer: European Society for Medical Oncology Clinical Practice Guidelines.

  2015cited by this paper
• Predictive Factors for BRCA1 and BRCA2 Genetic Testing in an Asian Clinic-Based Population

  2015cited by this paper
• Family History and Risk of Endometrial Cancer: A Systematic Review and Meta-analysis

  2015influential reference
• Integrative clinical genomics of advanced prostate cancer.

  2015cited by this paper
• Genomic era diagnosis and management of hereditary and sporadic colon cancer.

  2014cited by this paper
• Menopausal hormone therapy and risk of endometrial cancer.

  2014cited by this paper
• Effect of screening sigmoidoscopy and screening colonoscopy on colorectal cancer incidence and mortality: systematic review and meta-analysis of randomised controlled trials and observational studies

  2014cited by this paper
• Clinical evaluation of a multiple-gene sequencing panel for hereditary cancer risk assessment.

  2014cited by this paper
• Pancreatic cancer.

  2013cited by this paper
• Author Manuscript

  2013cited by this paper
• Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.

  2013cited by this paper
• Incorporating genomics into breast and prostate cancer screening: assessing the implications

  2013cited by this paper
• BRCA2 Mutations and Triple-Negative Breast Cancer

  2012influential reference
• Prevalence of BRCA1 mutations among 403 women with triple-negative breast cancer: implications for genetic screening selection criteria: a Hellenic Cooperative Oncology Group Study

  2012cited by this paper
• BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group.

  2012cited by this paper
• Review of biomarkers in colorectal cancer

  2012cited by this paper
• Chapter 11: Challenges in and Principles for Conducting Systematic Reviews of Genetic Tests used as Predictive Indicators

  2012cited by this paper
• Risk-based prostate cancer screening.

  2012cited by this paper
• Germline mutations in HOXB13 and prostate-cancer risk.

  2012cited by this paper
• Molecular pathways in colorectal cancer

  2012cited by this paper
• Drug therapy for hereditary cancers

  2011cited by this paper
• Dietary Fat, Fiber, and Carbohydrate Intake in Relation to Risk of Endometrial Cancer

  2011cited by this paper
• How much colonoscopy screening should be recommended to individuals with various degrees of family history of colorectal cancer?

  2011cited by this paper
• Primary appendiceal mucinous adenocarcinoma in two first-degree relatives: case report and review

  2011cited by this paper
• Interest in Genetic Testing for Modest Changes in Breast Cancer Risk: Implications for SNP Testing

  2011influential reference
• Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer.

  2011cited by this paper
• Colon cancer.

  2010cited by this paper
• The inherited genetics of ovarian and endometrial cancer.

  2010cited by this paper
• Primary prevention of colorectal cancer.

  2010cited by this paper
• Hereditary and familial colon cancer.

  2010influential reference
• High Cancer Risk in Peutz–Jeghers Syndrome: A Systematic Review and Surveillance Recommendations

  2010cited by this paper
• Hereditary pancreatic cancer.

  2010cited by this paper
• Physical activity, sedentary behaviours, and the prevention of endometrial cancer

  2010cited by this paper
• Hereditary ovarian cancer.

  2009influential reference
• Genome-wide association study of ulcerative colitis identifies three new susceptibility loci, including the HNF4A region

  2009cited by this paper
• Family history of cancer and the risk of endometrial cancer

  2009cited by this paper
• Meta-analysis of BRCA1 and BRCA2 penetrance.

  2007cited by this paper

• No citing papers are available for this paper.